A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma- A North Central Cancer Treatment Group Study, N057E1
      QxMD      Google Scholar   
Citation:
Cancer vol 117 (8)
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
560   565   571   651  
Children:
None
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA035267, U10 CA025224-25, U10 CA052352, U10 CA037417, N01 CA035431, U10 CA035269, CA-37404, CA-35090, CA-52352, CA-35195, U10 CA037404, N01 CA035119, U10 CA063848, U10 CA035195, CA-35103, CA-25224, CA-35113, U10 CA035101, U10 CA035113, CA-63848, U10 CA035415, U10 CA063849, CA-35415, U10 CA035431, U10 CA035119, CA-37417, CA-35269, CA-35101, U10 CA025224, U10 CA035090, CA-35267, CA-63849, U10 CA035103  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
NCCTG-N057E
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
metastatic melanoma, nab-paclitaxel, carboplatin, chemotherapy, stage IV, unresectable